Response to “Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway”

In the absence of solid data for every parameter, "best available evidence" should be used, while potential consequences of uncertainties and methodological controversies should be explored using sensitivity and scenario analyses. The two second generation pneumococcal conjugate vaccines (PCV13, and PHiD-CV) both lack AOM efficacy data, thus it was necessary to extrapolate from previous vaccine formulations.